Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Methylated- DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma

1 Nov 2008

Abstract excerpt

BACKGROUND: MYCN amplification (MNA) in neuroblastoma is a strong indicator of poor prognosis. However, some MYCN nonamplified (non-MNA) cases show poor outcomes, and examining the status of the gene requires an operation, which may have surgical complications. Therefore, a new marker is needed to identify cases of non-MNA neuroblastomas with poor prognoses using less risky procedures. Aberrant hypermethylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Erythrocyte Function and Pathophysiology
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18980997
DOI: 10.1158/1078-0432.ccr-08-1249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Methylated- DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified NeuroblastomaPMID 18980997Read ↗

Prediction of <i>MYCN</i> Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain ReactionSemantic proximity Read ↗

A systematic review of circulating-free MYCN amplification status as a noninvasive and prominent prognostic and recurrence monitoring indicator for neuroblastomaSemantic proximity Read ↗

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in NeuroblastomaSemantic proximity Read ↗

Plasma circulating cell-free MYCN gene: a noninvasive and prominent recurrence monitoring indicator of neuroblastomaSemantic proximity Read ↗

Methylation of<i>CASP8, DCR2</i>, and<i>HIN-1</i>in Neuroblastoma Is Associated with Poor OutcomeSemantic proximity Read ↗

Evaluation of Minimal Residual Disease in Patients with NeuroblastomaSemantic proximity Read ↗

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastomaSemantic proximity Read ↗

Adrenergic and mesenchymal signatures are identifiable in cell‐free DNA and correlate with metastatic disease burden in children with neuroblastomaSemantic proximity Read ↗

Detection of <i>MYCN</i> Amplification in Serum DNA Using Conventional Polymerase Chain ReactionSemantic proximity Read ↗

The Doublecortin Gene, A New Molecular Marker to Detect Minimal Residual Disease in NeuroblastomaSemantic proximity Read ↗

A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patientsSemantic proximity Read ↗

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease PanelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.